Evidence map›Paper›PMID 39858572›Full record

ArticleGenes2024

Novel Splice-Altering Variants in the

Anna R Ridgeway, Ciara Shortall, Laura K Finnegan, Róisín Long, Evan Matthews, Adrian Dockery, Ella Kopčić, Laura Whelan, Claire Kirk, Giuliana Silvestri and 7 more

Abstract read
In one paragraph

Article in Genes, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Anna R RidgewayThe School of Genetics and Microbiology, Trinity College Dublin, Dublin 2, D02 VF25 Dublin, Ireland.ORCID 0009-0005-3533-3395
Ciara ShortallThe School of Genetics and Microbiology, Trinity College Dublin, Dublin 2, D02 VF25 Dublin, Ireland.
Laura K FinneganThe School of Genetics and Microbiology, Trinity College Dublin, Dublin 2, D02 VF25 Dublin, Ireland.ORCID 0000-0002-3395-1211
Róisín LongThe School of Genetics and Microbiology, Trinity College Dublin, Dublin 2, D02 VF25 Dublin, Ireland.
Evan MatthewsThe School of Genetics and Microbiology, Trinity College Dublin, Dublin 2, D02 VF25 Dublin, Ireland.
Adrian DockeryThe School of Genetics and Microbiology, Trinity College Dublin, Dublin 2, D02 VF25 Dublin, Ireland.ORCID 0000-0002-3423-2542
Ella KopčićThe School of Genetics and Microbiology, Trinity College Dublin, Dublin 2, D02 VF25 Dublin, Ireland.ORCID 0000-0002-3977-851X
Laura WhelanThe School of Genetics and Microbiology, Trinity College Dublin, Dublin 2, D02 VF25 Dublin, Ireland.ORCID 0000-0002-0537-4349
Claire KirkDepartment of Ophthalmology, The Royal Victoria Hospital, Belfast BT12 6BA, UK.
Giuliana SilvestriDepartment of Ophthalmology, The Royal Victoria Hospital, Belfast BT12 6BA, UK.ORCID 0000-0001-5662-5374
Jacqueline TurnerClinical Ophthalmic Genetics Unit, The Mater Misericordiae University Hospital, D07 K201 Dublin, Ireland.
David J KeeganClinical Ophthalmic Genetics Unit, The Mater Misericordiae University Hospital, D07 K201 Dublin, Ireland.
Sophia Millington-WardThe School of Genetics and Microbiology, Trinity College Dublin, Dublin 2, D02 VF25 Dublin, Ireland.ORCID 0000-0001-7470-0702
Naomi ChaddertonThe School of Genetics and Microbiology, Trinity College Dublin, Dublin 2, D02 VF25 Dublin, Ireland.ORCID 0000-0002-1684-1598
Emma DuignanDepartment of Ophthalmology, Royal Victoria Eye and Ear Hospital, Dublin 2, D02 XK51 Dublin, Ireland.
Paul F KennaThe School of Genetics and Microbiology, Trinity College Dublin, Dublin 2, D02 VF25 Dublin, Ireland.
G Jane FarrarThe School of Genetics and Microbiology, Trinity College Dublin, Dublin 2, D02 VF25 Dublin, Ireland.

Funding

Fighting Blindness FB22FAR, FB16FARHealth Research Charities Ireland MRCG-2016-14Irish Research Council GOIPG/2017/1631Science Foundation Ireland 16/IA/4452 and 22/FFP-A/10544
6 · The paper itself

Abstract

backgroundAn estimated 10-15% of all genetic diseases are attributable to variants in noncanonical splice sites, auxiliary splice sites and deep-intronic variants. Most of these unstudied variants are classified as variants of uncertain significance (VUS), which are not clinically actionable. This study investigated two novel splice-altering variants,

methodsNext-generation sequencing was employed to identify the candidate variants in

resultsMidigene functional analysis confirmed that both variants disrupted splicing. The

conclusionsThis study adds to the mutational spectrum of splicing defects implicated in retinal degenerations by identifying and characterising two novel variants in

Indexed as

Adaptor Proteins, Signal TransducingCalcium Channels, L-TypeChoroideremiaCone DystrophyGenetic Diseases, X-LinkedAdultFemaleHEK293 CellsHigh-Throughput Nucleotide SequencingHumansMaleMiddle AgedMutationPedigreeRNA Splice SitesRNA SplicingAdaptor Proteins, Signal TransducingCACNA1F protein, humanCalcium Channels, L-TypeCHM protein, humanRNA Splice Siteschoroideremiacone dystrophyfunctional analysismidigene splice assayssplicingvariant interpretationvariant of uncertain significance

Identifiers

PMID39858572
PMCPMC11764614

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.